# ROFEL Shri G M Bilakhia College of Pharmacy

*Experience Innovation in Education*

Approved by Pharmacy Council of India (PCI) and Affiliated to GUJARAT TECHNOLOGICAL UNIVERSITY (GTU), AHMEDABAD

An ISO 9001:2015 & ISO 29990:2010 Certified Institution • NAAC Accredited B++ Grade Institution



## Our thoughts of Month

*Don't let*
**YESTERDAY**
*use up*
*too much of*
**TODAY**

*-Will Rogers*

**ROFEL Shri G M Bilakhia College of Pharmacy, Vapi**
Rofel-Namdha Campus , VAPI-Namdha
Road, Vapi-396191
Contact Number- 9727723722
Email: rofelpharm@gmail.com
Website: www.rofelpharma.org
Follow us on:

# INSTITUTE AFFAIRS

## ONLINE REFRESHER COURSE

ROFEL Shri G.M. Bilakhia College of Pharmacy – A constituent college of Rajju Shroff ROFEL University has organized two days online Refresher course sponsored by Gujarat State Pharmacy Council for registered pharmacists on 25th and 26th November, 2023 on virtual Platform using zoom meeting. Gujarat State Pharmacy Council has made refresher course mandatory for all registered pharmacist with the aim to help pharmacist to acquire knowledge of recent trends. There were in all 400 registration received during the course amongst them 241 successfully attended all the session, appeared for the examination and duly submitted the feedback form also. Therefore the e-certificates based on monitoring of attendance and examination was issued to 231 registered pharmacists only. The inauguration ceremony commenced with Saraswati Vandana. Dr. Kishor Dholwani – Principal, Sardar Patel College of Pharmacy, Bakrol, Anand - guest of honor inaugurated the refresher course and in his inaugural address he welcomed the gathering and explained the importance of the course and pharmacist in community health care.

Dr. Arindam Paul – I/C Provost of Rajju Shroff ROFEL University and Principal of ROFEL Shri G.M. Bilakhia College of Pharmacy welcomed the gathering and honoured the dignitaries. In his keynote address he explained the need for updating and enriching the knowledge for the professional competence and career advancement to face the challenges. Dr. Ankita Patel Course Coordinator also welcomed the delegates and encourage participant to actively participate in all sessions.


Dr. Arindam Paul delivering his welcome keynote address


# PHARMA NEWS

PHARMA NEWS

Vol-8 : MAR - APR, 2019 FOR PRIVATE CIRCULATION ONLY

**India poised for best decade in growth, says Rakesh Jhunjhunwala**

Big Bull Rakesh Jhunjhunwala says India will outpace the growth record past decade over the next 10 years, powered by th e fruits of GST, demonetisation and other big economic reforms.

He also expects huge growth in capital expenditure and foreign investment in the coming decade.

In an interaction with ETNow, the ace stock picker said the worst effects of goods and services tax (GST) and demonetisation are behind us and it is now time to enjoy the good effects of these reforms, which will be reflected in the GDP going forward.

Jhunjhunwala said while some people think Prime Minister Narendra Modi did a crime by implementing reforms like note ban and GST, the real benefits of the same will start showing now.

"If you see the experience of other countries, they took five to seven years to stabilise, we have stabilised in a year. India is going to see one of the fastest rates of growth. I see more money coming into the market," the ace investor said. He said one should not lose sight of the fact that India is growing on a higher base. "We have reached a situation where discretionary expenditure is going to hit the roof. I think people believe in stocks but they do not believe in the economy," he said.

Sharing his insights on the sustained flow of foreign institutional investment into domestic equities, Jhunjhunwala said he was surprised by the recent rally in stock markets globally.

Foreign institutional investors (FII) have poured over Rs 61,000 crore in Indian equities so far this year against an outflow of Rs 32,600 crore in 2018.

"We have to accept that low interest rates are here to stay and this acceptance has led to more money coming into equity, resulting higher PE. I think that is why emerging markets are in a much better situation in terms of currency and growth than they were ever in history," he said

Jhunjhunwala is bullish on banks, pharma and infrastructure sectors. He expects select opportunities in public sector companies, considering their attractive valuations.

Sharing his insights on the pharma sector, he said, "The price erosion is behind us. Indian pharma market will tend to grow faster than it has grown. Pharma is not a market where demand can go down. You must know that 40-45 per cent of all medicines used in the US is made in India. I think it is a sunrise industry, it is not a sunset industry, it can never be a sunset industry."

"In the next decade, the performance of Indian economy and the market will be far better. The last decade was partly a lost decade," he said.

As per a PTI report Jhunjhunwala said the poor have not benefited from the bull run in equities in the past four decades. "We need to stand guard against populist moves like wealth tax," the investing veteran said at the launch of ITI Mutual Fund, the 41st AMC to have set up shop in the country.

He said the poor, who have missed out on personal growth opportunities, decide governments through their votes and the leaders they choose serve the core constituency.

Citing the example of the US, where one of the nominees of the next presidential race has promised to impose wealth tax, he said similar moves will be implemented across the world if the trend continues.

PTI report also quoted Jhunjhunwala as saying that another factor he is worried about is the possibility of a nuclear attack by Pakistan, adding there are enough rogue elements in that country who may not hesitate to use the N-button.

Source : economictimes.indiatimes

01

GUBBA PHARMA COLD STORAGE

GUBBA PHARMA NEWS

Vol-9 : July - Aug. 2019 FOR PRIVATE CIRCULATION ONLY

SUN

**Once India's richest man, this pharma tycoon valued his anonymity over wealth**

*(Dilip Shanghvi worked his way up from a tiny shop in the bylanes of Kolkata in the 1970s to create one of India's most valuable enterprises—Sun Pharmaceuticals. The billionaire is known for his frugal and reticent ways.)*

Shanghvi's ascension to the peak of the Indian pharmaceuticals pyramid nearly coincided with a much larger historic event, not only for him (though he is likely to dismiss it), but for the country. Celebrated rich lists had already pronounced him the world's wealthiest pharma entrepreneur, Asia's only non-realty tycoon in the top ten wealthiest men, richest self-made Indian, but none of it had had the earth-shattering effects to them, as the pronouncement made by Forbes and Bloomberg in March 2015.

Shanghvi with his net worth pegged at $21 billion (Rs1.5 lakh crore at current rates) had dethroned Mukesh Ambani to become the richest Indian. Albeit short-lived, not to last beyond months, it was a moment of axial tilt for India in many ways—and not the least because the Ambanis, who had been a synonym of wealth and power in the collective memory of this country, had never been toppled from that much-envied seat since the wealth indices started applying to this part of the world.

In a welcome change, India's richest man hadn't inherited his riches; hadn't earned his fortune through cronyish connections or government concessions—common in sectors like energy, infrastructure or even telecom; hadn't multiplied wealth by some gamble in finance or real estate. Shanghvi had earned his wealth not even by building a conglomerate, but by dint of focusing just on one sector—pharmaceuticals.

**In a welcome change, India's richest man hadn't inherited his riches.**

American academic Caroline Freund bracketed him in a select list of "Schumpeterian" entrepreneurs, who were building and managing big companies that fought for their lives in the global markets, "a healthy consequence of structural transformation and rapid development" of the (country's) economy. Yet, you don't have to be a businessman in India to know that cronyism is far from dead. But Shanghvi's climb to the zenith of the wealth ladder stood for a hope, that meritocracy still has a chance. As the news spread like wildfire, Indians beyond the finance world, doctors, and the pharmaceuticals industry woke up to a surname—Shanghvi, and the man who so prized and preserved his oblivion became a subject of national curiosity.

Pink papers realised that despite knowing him, they knew very little of his personal story to satisfy that curiosity. In that state of ill-preparedness, editors struggled to find a league to put Shanghvi in. Newsrooms debated whether he seemed closer to the league of Narayana Murthy and Azim Premji, but rejected it on the ground that he had shown far little commitment to philanthropy.

They were in consensus that he surely didn't belong to the league of the Ambanis or Adanis, and was far removed from the Tatas and Birlas. Without exception, all financial magazines and newspapers scrambled for an appointment with him and with or without managing one, put him on cover and page ones.

Shortly after, on a trip to China for his company's annual star awards on a rented private chartered plane, when Shanghvi was explaining to friend Sailesh Desai why he thought eggs are not non-vegetarian, his then India CEO Abhay Gandhi walked up to the magazine stands and started to flip through the pages.

**Shanghvi didn't belong to the league of the Ambanis or Adanis.**

Desai called him from behind, asking, "Is there anything worth reading?" Gandhi turned around holding up two magazines—Business Today and Outlook Business, both of which had the same face on their covers—Shanghvi's. This newly aroused curiosity about him spilled over to social media with questions on Quora like "Why is Dilip Shanghvi not much talked about as compared to Mukesh Ambani even though he's the richest person in India?" and **"Why is India's richest person (Dilip Shanghvi) so simple when compared to some of India's richest men?"**

His profiles on web multiplied by the day, and a Twitter handle that was not his surfaced and continued to tweet opinions on his name for well over two years. A friend Piyush Doshi, who had once messaged him saying he was not happy to see him at No. 2 on India's rich list, because he hoped to see him at No. 1, finally punched a congratulatory text. The boy Jai Shah who had seen him lift buckets of water from a common tube well for bath in the Paddapukur building in Calcutta, gasped with excitement as he compared the **"extravagant opulence of Ambanis with the austere living of Dilip uncle."**

A wife of a friend who had not a long time back seen him fix the dent of their Maruti

01